{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T08:35:08Z","timestamp":1793781308667,"version":"4.6.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ejca.2026.116264","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T07:47:18Z","timestamp":1769759238000},"page":"116264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Use of concomitant G-CSF in maintaining efficacious dose and safe delivery of docetaxel in combination with darolutamide in ARASENS: A phase III study"],"prefix":"10.1016","volume":"236","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0347-5541","authenticated-orcid":false,"given":"Michael","family":"Ong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyoshi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0093-8408","authenticated-orcid":false,"given":"Bertrand","family":"Tombal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6068-9474","authenticated-orcid":false,"given":"Karim","family":"Fizazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Verholen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ha","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankar","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9907-9112","authenticated-orcid":false,"given":"Aly-Khan A.","family":"Lalani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ejca.2026.116264_bib1","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","article-title":"Updates to advanced prostate cancer: AUA\/SUO guideline (2023)","volume":"209","author":"Lowrance","year":"2023","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.ejca.2026.116264_bib2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.eururo.2024.09.017","article-title":"Management of patients with advanced prostate cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)","volume":"87","author":"Gillessen","year":"2025","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.ejca.2026.116264_bib3","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.annonc.2023.02.015","article-title":"Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents","volume":"34","author":"Fizazi","year":"2023","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2026.116264_bib4","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer\u20142024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/j.ejca.2026.116264_bib5","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116264_bib6","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1200\/JCO.23.00041","article-title":"Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial","volume":"41","author":"Hussain","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2026.116264_bib7","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/oncolo\/oyac074","article-title":"Chemotherapy-induced neutropenia and febrile neutropenia in the US: a beast of burden that needs to be tamed?","volume":"27","author":"Boccia","year":"2022","journal-title":"Oncologist"},{"issue":"12","key":"10.1016\/j.ejca.2026.116264_bib8","first-page":"825","article-title":"Management of neutropenia in cancer patients","volume":"10","author":"Lustberg","year":"2012","journal-title":"Clin Adv Hematol Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2026.116264_bib9","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1177\/1758834017692779","article-title":"Docetaxel in prostate cancer: a familiar face as the new standard in a hormone-sensitive setting","volume":"9","author":"Puente","year":"2017","journal-title":"Ther Adv Med Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2026.116264_bib10","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.euf.2023.03.024","article-title":"Triplet or doublet therapy in metastatic hormone-sensitive prostate cancer: updated network meta-analysis stratified by disease volume","volume":"9","author":"Hoeh","year":"2023","journal-title":"Eur Urol Focus"},{"issue":"8","key":"10.1016\/j.ejca.2026.116264_bib11","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejca.2026.116264_bib12","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","article-title":"Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial","volume":"14","author":"Gravis","year":"2013","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2026.116264_bib13","doi-asserted-by":"crossref","first-page":"315","DOI":"10.21037\/tau.2017.02.01","article-title":"Treatment of metastatic prostate cancer after STAMPEDE","volume":"6","author":"Wolf","year":"2017","journal-title":"Transl Androl Urol"},{"issue":"10024","key":"10.1016\/j.ejca.2026.116264_bib14","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.ejca.2026.116264_bib15","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.clon.2016.06.006","article-title":"Febrile neutropenia rates in men treated with docetaxel chemotherapy for metastatic hormone-sensitive prostate cancer","volume":"28","author":"Mahil","year":"2016","journal-title":"Clin Oncol (R Coll Radio)"},{"issue":"4","key":"10.1016\/j.ejca.2026.116264_bib16","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s11136-022-03302-z","article-title":"Health-related quality of life in patients newly diagnosed with prostate cancer: CAPLIFE study","volume":"32","author":"Lozano-Lorca","year":"2023","journal-title":"Qual Life Res."},{"issue":"10336","key":"10.1016\/j.ejca.2026.116264_bib17","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u00d72 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.ejca.2026.116264_bib18","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1080\/17474086.2022.2093712","article-title":"G-CSF primary prophylaxis use and outcomes in patients receiving chemotherapy at intermediate risk for febrile neutropenia: a scoping review","volume":"15","author":"Campbell","year":"2022","journal-title":"Expert Rev Hematol"},{"issue":"5","key":"10.1016\/j.ejca.2026.116264_bib19","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s10147-024-02501-7","article-title":"Effectiveness and safety of primary prophylaxis of G-CSF during chemotherapy for prostate cancer, Japanese clinical guideline for appropriate use of G-CSF: clinical practice guidelines for the use of G-CSF 2022","volume":"29","author":"Kimura","year":"2024","journal-title":"Int J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2026.116264_bib20","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s00280-020-04063-7","article-title":"Docetaxel dose-intensity effect on overall survival in patients with metastatic castrate-sensitive prostate cancer","volume":"85","author":"Kushnir","year":"2020","journal-title":"Cancer Chemother Pharm"},{"issue":"9","key":"10.1016\/j.ejca.2026.116264_bib21","doi-asserted-by":"crossref","first-page":"e1609","DOI":"10.1002\/onco.13822","article-title":"Relative dose intensity of chemotherapy and survival in patients with advanced stage solid tumor cancer: a systematic review and meta-analysis","volume":"26","author":"Nielson","year":"2021","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.ejca.2026.116264_bib22","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12894-019-0463-7","article-title":"A retrospective feasibility study of biweekly docetaxel in patients with high-risk metastatic castration-naive prostate cancer","volume":"19","author":"Yoon","year":"2019","journal-title":"BMC Urol"},{"issue":"28","key":"10.1016\/j.ejca.2026.116264_bib23","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","article-title":"Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline update","volume":"33","author":"Smith","year":"2015","journal-title":"J Clin Oncol"},{"issue":"5_suppl","key":"10.1016\/j.ejca.2026.116264_bib24","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1200\/JCO.2025.43.5_suppl.152","article-title":"Concomitant G-CSF use in maintaining an efficacious dose and safe delivery of docetaxel in combination with darolutamide in patients with metastatic hormone sensitive prostate cancer (mHSPC): ARASENS, a phase 3 study","volume":"43","author":"Ong","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116264_bib25","article-title":"Group EGW. Hematopoietic growth factors: ESMO recommendations for the applications","volume":"20 Suppl 4:1625","author":"Crawford","year":"2009","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2026.116264_bib26","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s10147-024-02501-7","article-title":"Effectiveness and safety of primary prophylaxis of G-CSF during chemotherapy for prostate cancer, Japanese clinical guideline for appropriate use of G-CSF: clinical practice guidelines for the use of G-CSF 2022","volume":"29","author":"Kimura","year":"2024","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116264_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.clon.2018.07.036","article-title":"Incidence of febrile neutropenia in docetaxel chemotherapy without prophylactic granulocyte-colony stimulating factor (GCSF) for metastatic prostate cancer","volume":"30","author":"Renninson","year":"2018","journal-title":"Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2026.116264_bib28","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s12032-016-0793-1","article-title":"Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer","volume":"33","author":"Schweizer","year":"2016","journal-title":"Med Oncol"},{"issue":"28","key":"10.1016\/j.ejca.2026.116264_bib29","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","article-title":"Recommendations for the use of WBC Growth Factors: American Society of Clinical Oncology clinical practice guideline update","volume":"33","author":"Smith","year":"2015","journal-title":"J Clin Oncol"},{"issue":"10336","key":"10.1016\/j.ejca.2026.116264_bib30","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u202f\u00d7\u202f2 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ejca.2026.116264_bib31","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.critrevonc.2013.12.006","article-title":"Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review","volume":"90","author":"Lyman","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"10.1016\/j.ejca.2026.116264_bib32","first-page":"311","article-title":"Incidence, predictors, and outcomes of febrile neutropenia and neutropenia in patients with metastatic castrate-resistant prostate cancer receiving docetaxel","volume":"31","author":"Peltekian","year":"2023","journal-title":"Support Care Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2026.116264_bib33","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/cas.12647","article-title":"Pharmacokinetics, dynamics and toxicity of docetaxel: why the Japanese dose differs from the Western dose","volume":"106","author":"Kenmotsu","year":"2015","journal-title":"Cancer Sci"},{"issue":"2","key":"10.1016\/j.ejca.2026.116264_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14020407","article-title":"Ethnic pharmacogenomic differences in the management of asian patients with metastatic prostate cancer","volume":"14","author":"Poon","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2026.116264_bib35","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221131525","article-title":"Efficacy and safety of therapies for advanced prostate cancer in Asia: Evidence from a systematic literature review","volume":"14","author":"Saad","year":"2022","journal-title":"Ther Adv Med Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2026.116264_bib36","first-page":"481","article-title":"Management of advanced prostate cancer in the Asia-Pacific region: summary of the asia-pacific advanced prostate cancer consensus Conference 2023","volume":"20","author":"Chiong","year":"2024","journal-title":"Asia Pac J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2026.116264_bib37","doi-asserted-by":"crossref","first-page":"195","DOI":"10.47102\/annals-acadmedsg.V46N5p195","article-title":"Outcomes of dose-attenuated docetaxel in asian patients with castrate-resistant prostate cancer","volume":"46","author":"Ang","year":"2017","journal-title":"Ann Acad Med Singap"},{"key":"10.1016\/j.ejca.2026.116264_bib38","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/ajco.13578","article-title":"Prevention of docetaxel-associated febrile neutropenia with primary granulocyte colony-stimulating factor in Chinese metastatic hormone-sensitive and castration-resistant prostate cancer patients","volume":"17 Suppl 3","author":"Poon","year":"2021","journal-title":"Asia Pac J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2026.116264_bib39","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s00280-022-04433-3","article-title":"Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients","volume":"89","author":"Vermunt","year":"2022","journal-title":"Cancer Chemother Pharm"},{"issue":"12","key":"10.1016\/j.ejca.2026.116264_bib40","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1093\/annonc\/mdt397","article-title":"Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials","volume":"24","author":"Templeton","year":"2013","journal-title":"Ann Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926000444?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926000444?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T16:16:35Z","timestamp":1779380195000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926000444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":40,"alternative-id":["S0959804926000444"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116264","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of concomitant G-CSF in maintaining efficacious dose and safe delivery of docetaxel in combination with darolutamide in ARASENS: A phase III study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116264","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116264"}}